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OBJECTIVES: Clinical trials have reported A1C reductions of 0.7% over 24 weeks 
for sitagliptin monotherapy and when added to metformin (baseline A1C  8.0%
 for both). When added to pioglitazone the mean A1C reduction was 0.9% (baseline 
A1C  8.1%). With monotherapy 45% of patients achieved A1C  7.0%. METHODS:
Patient characteristics and real-world effectiveness of sitagliptin were investigated using
a large US claims database. Patients with new prescription claims for sitagliptin 
between 10/1/06 and 3/31/07 and q12 months pre- and post-index eligibility were 
included (n  3719). Mean (SD) age was 56.0 (o10.0) and 39% were female. Co-
morbidities included: hypertension (84%), dyslipidemia (83%), and other cardiovas-
cular disease (25%). The starting dose was 100 mg for 93% of patients. Concomitant
antihyperglycemic medications at index (100 to 15 days post index) included met-
formin (58%), thiazolidinediones (41%), sulfonylureas (37%) and insulin (16%).
Seven percent had no concomitant antihyperglycemic medications. RESULTS: The 
mean (SD) number of concomitant medications was 1.9 (o1.0). Insulin use increased
from 16% to 25% (p  .0001), in the 12 month post-index period. Other concomitant 
medications showed little change. The medication possession ratio (days supply/365
days) in patients with 1 prescription claim was 74 o 29%. Clinical effectiveness was
measured in patients with baseline (6 months pre-index – 1 month post index) and 
post-index (60–365 days) A1C data (n  102). Mean (SD) baseline A1C was 7.6%
(o1.0) with an absolute reduction of 0.2% (o1.1) [mean duration of follow-up  246.0
(o81.6) days]. Of 72 patients with a baseline A1C q7.0%, 21 (29%) achieved an A1C 
goal of 7.0%. CONCLUSIONS: This study reports real-world analyses of sitagliptin
patient characteristics and effectiveness. Adherence to therapy was similar to that for 
other oral antihyperglycemic drugs, but mean reduction in A1C and percent to goal 
were less than in clinical trials, despite an increase in the percent of patients using 
insulin.
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OBJECTIVES: To compare dosing patterns between duloxetine and pregabalin among 
patients with diabetic peripheral neuropathic pain (DPNP). METHODS: Using a large
administrative claims database in the United States, we examined commercially 
insured individuals aged 18–64 who dispensed duloxetine or pregabalin in 2006. The
date of the ﬁ rst duloxetine or pregabalin prescription dispensed was deﬁ ned as the
index date. All patients selected were diagnosed with DPNP and had continuous 
enrollment over the 12-month pre- index period. Each patient was classiﬁ ed in the 
duloxetine or pregabalin cohorts based on the index agent, and all duloxetine or pre-
gabalin prescriptions ﬁ lled over the 12-month follow-up period were examined. We 
compared the average daily dose of all prescriptions per person, average daily dose in 
each of the ﬁ rst 10 prescriptions, and percent of daily dose change from previous
prescription between duloxetine and pregabalin cohorts. RESULTS: Among 603 
duloxetine patients and 1751 pregabalin patients, the average daily doses of all pre-
scriptions were 51.2mg and 179.8mg for duloxetine and pregabalin, respectively. The
average daily doses for the 1st and 10th duloxetine scripts were 53.8mg (95% Conﬁ -
dence Interval (CI): 52.4, 55.2) and 64.9mg, while the numbers were 166mg (95%
CI: 162, 170) and 264.3mg (95% CI: 244.1, 284.4) for pregabalin. The changes in 
daily doses from previous prescription were 0.2–4.0% for duloxetine and 0.8–12.5%
for pregabalin, respectively. The percentage of change in daily dose from the 1st to 
10th prescription was signiﬁ cantly higher for pregabalin (59.2%) than for duloxetine
(20.7%) (p  0.05). CONCLUSIONS: DPNP patients on duloxetine or pregabalin 
experienced very different dosing patterns. The average daily dose for duloxetine was
relatively stable over time, while pregabalin patients had signiﬁ cant dose escalation
over the 12-month follow-up period.
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THE EFFECTS OF SUSTAINED-RELEASE GLIPIZIDE VERSUS GLICLAZIDE
FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF
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OBJECTIVES: There are currently many kinds of sulphonylurea agents taken as the 
ﬁ rst-line drugs for patients with diabetes. As the second-generation sulfonylureas, 
we try to explore the comparative efﬁ cacy and safety of sustained-release glipizide 
and gliclazide for type 2 diabetes mellitus. METHODS: A systematic review of ran-
domized controlled trials (RCTs) was conducted. PUBMED, EMBASE, The Cochrane 
Library, three Chinese Databases (CBM, CNKI, and VIP), as well as the citations or
reference lists were searched from their inception to July 31, 2008. The pharmaceutical 
companies were contacted for unpublished studies. Trial selection, quality assessment
and data extraction were performed by two reviewers independently. We pooled
the trial data using the random-effect model and explored the heterogeneity by the 
pre-speciﬁ ed variables. RESULTS: Only two trials (n  190) compared the extended-
release glipizide with gliclazide based on the treatment of metformin or acarbose and 
diet control. The quality of included trials was poor. Only randomized trials were
mentioned without detailed information on the methods of generating randomization 
sequences, concealment allocation, and blinding. The durations of follow-up(12 
weeks) were too short to obtain the long-term effects of the diabetes-related morbidity 
and mortality. Both sustained-release glipizide and gliclazide had signiﬁ cantly reduced 
HbA1c, fasting and postprandial blood glucose from baseline to the end of treatment. 
However, there was no signiﬁ cant difference between groups, including the changes
of HbA1c (weighted mean difference  0.13, 95%CI  0.21 to 0.46), fasting blood 
glucose (0.07 [0.67, 0.52]), and postprandial blood glucose (1.40 [0.80, 3.60]).
There is similar safe proﬁ les in hypoglycemia, changes of lipid and body weight, and 
liver and renal functions. CONCLUSIONS: The limited evidence showed that both 
sustained-release glipizide and gliclazide are effective in glucose control with similar
effects and safe proﬁ le. More high-quality RCTs are expected to explore the effects of 
different sulfonylurea agents.
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OBJECTIVES: Health care costs for adherent patients were compared with costs for 
nonadherent patients in a cohort with diabetes mellitus taking metformin, sulfonyl-
ureas, or pioglitazone. METHODS: Using both, the commercial and Medicare supple-
mental MEDSTAT MarketScan research databases, a retrospective cohort study 
identiﬁ ed 108,592 continuously insured patients 18 to 90 years of age with diabetes 
mellitus (ICD-9-CM 250.xx) using metformin, sulfonylureas, or pioglitazone mono-
therapy during 2003. Adherence was calculated in 2004 and 2005 using a medication
possession ratio, and dichotomized at q80% to indicate adherence. Total health care 
costs included insurer payments and patient cost-sharing from medical (inpatient, 
outpatient) and prescription drug claims. Diabetes-speciﬁ c costs included pharmacy 
claims for any diabetes drug and medical claims containing a primary diagnosis of 
diabetes or a diabetes complication. Multivariate analysis was conducted to adjust for 
potential confounders. RESULTS: During the initial year of follow-up, the proportion 
of patients adherent to treatment were 57%, 61%, and 59% for metformin, sulfonyl-
ureas, and pioglitazone, respectively. Annual unadjusted total health care costs were
consistently lower for adherent patients than for non-adherent patients ($1470 less 
for metformin users, $3734 less for sulfonylurea users, and $3477 for pioglitazone 
users). In the multivariate models, total health care costs and diabetes speciﬁ c health 
care costs respectively were $846 (95% CI $747 to $945) and $55 (95% CI $33 to 
$77) per year lower for adherent patients compared to nonadherent patients. The 
adjusted annual adherence-related cost difference was $336 for metformin (95% CI
$216 to $456), $1509 for sulfonylureas (95% CI $1339 to $1679), and $1,140 for 
pioglitazone (95% CI $793 to $1486). Annual cost differences were larger among 
Medicare plans compared with commercial insurance plans ($2220 lower vs $65 
higher, respectively). CONCLUSIONS: Adherence with oral diabetes medications
results in overall health care cost-savings. Both sulfonylureas and pioglitazone were
associated with larger total cost-savings than metformin.
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OBJECTIVES: To examine the association of Angiotensin Converting Enzyme inhibi-
tors (ACEI) and Angiotensin Receptor Blockers (ARBs) with Diabetes Nephropathy
or Chronic Renal Failure (DN/CRF), in patients with age 65 years or more with dia-
betes mellitus. METHODS: The study was a retrospective cohort study on elderly 
diabetic patients in the Veteran Affairs (VA). Exposure to ACEI and ARBs was 
observed in calendar year 2000 and outcomes (DN/CRF) were identiﬁ ed between
January 1, 2001 and September 30, 2001. Patients who received any diagnosis of renal
disease (DN/CRF) before 2001 and were on both ACEI and ARB were excluded. 
A Cox proportional hazards model was employed to examine the association
between time to DN/CRF diagnosis and exposure to ACEI or ARB. The confounders 
adjusted in the model included patient socio-demographics, co-morbidities, and co-
medications. RESULTS: The ﬁ nal cohort consisted of 427,124 patients with a mean 
age of 76 years. Majority of the patients were males (97.76%), whites (83.83%), in 
the age group of 76 to 85 years (48.32%). Cardiovascular comorbidities were 
common, with almost 80% of patients having hypertension, ischemic heart disease 
(IHD; 34%), and Chronic Heart Failure (CHF; 26%). A total of 2.76% of the 
patients from the ﬁ nal cohort developed DN/CRF. Multivariable analysis revealed that 
exposure to ACEI and ARBs is associated with increased risk of DN/CRF by 42% 
(95% CI 1.354–1.481) and 51% (95% CI 1.37–1.656) respectively. Many co-morbid
conditions (Hypertension, IHD, CHF) and all the co-medications adjusted in the 
model were signiﬁ cantly associated with increased risk of DN/CRF, with most pro-
minent association found in patients using insulin, antihypertensives, and diuretics.
CONCLUSIONS: Our study indicates that the use of agents that inhibit Renin-
Angiotensin-Aldosterone System (RAAS) do not prevent the development of DN/CRF.
